Clinical Trial

Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis

Name: Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis — clinical trial record (NCT04804553)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: PEAPOD

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The study will aim to estimate the efficacy of apremilast compared with placebo in the treatment of juvenile psoriatic arthritis (JPsA) in pediatric participants 5 to less than 18 years of age.

Trial Details

NCT Number	NCT04804553
Lead Sponsor	Amgen
Conditions	Active Juvenile Psoriatic Arthritis
Enrollment	60 participants
Start Date	2022-03-17
Primary Completion	2028-03-21 (estimated)
Study Completion	2028-12-29 (estimated)
Updated on ClinicalTrials.gov	2026-04-20